Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma

Phase 2

Terminated

Conditions: Ependymoma

Interventions: Drug: Carboplatin

First Posted Date: 2010-03-17

Last Posted Date: 2015-03-02

Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Target Recruit Count: 75

Registration Number: NCT01088035

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Pemetrexed
Drug: Cetuximab
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2010-03-16

Last Posted Date: 2014-05-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 69

Registration Number: NCT01087970

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States

A Study in Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Cetuximab
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-Fluorouracil

First Posted Date: 2010-03-05

Last Posted Date: 2019-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 187

Registration Number: NCT01081041

Locations: 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: paclitaxel
Drug: olaparib
Drug: carboplatin

First Posted Date: 2010-03-05

Last Posted Date: 2024-01-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 162

Registration Number: NCT01081951

Locations: 🇬🇧
Research Site, Edinburgh, United Kingdom

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase 3

Active, not recruiting

Conditions: Borderline Ovarian Mucinous Tumor
Stage IA Ovarian Cancer AJCC v6 and v7
Recurrent Fallopian Tube Carcinoma
Stage IIA Fallopian Tube Cancer AJCC v6 and v7
Stage IIB Ovarian Cancer AJCC v6 and v7
Stage IIIB Fallopian Tube Cancer AJCC v7
Stage IIIC Ovarian Cancer AJCC v6 and v7
Ovarian Mucinous Cystadenocarcinoma
Recurrent Ovarian Carcinoma
Stage IC Fallopian Tube Cancer AJCC v6 and v7

Interventions: Drug: Carboplatin
Drug: Capecitabine
Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Oxaliplatin
Other: Quality-of-Life Assessment

First Posted Date: 2010-03-05

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT01081262

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

and more 245 locations

Chemoradiation and Panitumumab for Esophageal Cancer

Phase 2

Completed

Conditions: Adenocarcinoma
Gastro-esophageal Junction Cancer
Squamous Cell Carcinoma
Esophageal Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: panitumumab
Radiation: radiotherapy

First Posted Date: 2010-03-02

Last Posted Date: 2021-04-21

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 78

Registration Number: NCT01077999

Locations: 🇳🇱
Academic Medical Center, Amsterdam, Netherlands

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Extensive-Stage Small Cell Lung Cancer

Interventions: Drug: Amrubicin
Drug: Carboplatin
Drug: Pegfilgrastim

First Posted Date: 2010-02-26

Last Posted Date: 2016-05-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 81

Registration Number: NCT01076504

Locations: 🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 17 locations

Ixabepilone + Carboplatin Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Ixabepilone
Drug: Carboplatin

First Posted Date: 2010-02-24

Last Posted Date: 2016-12-07

Lead Sponsor: US Oncology Research

Target Recruit Count: 103

Registration Number: NCT01075100

Locations: 🇺🇸
Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸
Missouri Cancer Associates, Columbia, Missouri, United States
🇺🇸
Southwest Cancer care, Murrieta, California, United States

and more 55 locations

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Mucinous Adenocarcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Mucinous Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma

Interventions: Drug: Bortezomib
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2010-02-24

Last Posted Date: 2019-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT01074411

Locations: 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States

and more 11 locations

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Lung Cancer

Interventions: Drug: Nexavar (Sorafenib, BAY43-9006)
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2010-02-17

Last Posted Date: 2013-11-13

Lead Sponsor: Bayer

Target Recruit Count: 33

Registration Number: NCT01069328

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy